-
1
-
-
84879759020
-
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
-
Hamid O, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134–144.
-
(2013)
N Engl J Med
, vol.369
, Issue.2
, pp. 134-144
-
-
Hamid, O1
-
2
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
-
(2010)
N Engl J Med
, vol.363
, Issue.8
, pp. 711-723
-
-
Hodi, FS1
-
3
-
-
84920956735
-
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
-
Herbst RS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–567.
-
(2014)
Nature
, vol.515
, Issue.7528
, pp. 563-567
-
-
Herbst, RS1
-
4
-
-
84920956732
-
PD-1 blockade induces responses by inhibiting adaptive immune resistance
-
Tumeh PC, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571.
-
(2014)
Nature
, vol.515
, Issue.7528
, pp. 568-571
-
-
Tumeh, PC1
-
5
-
-
84905083767
-
PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence
-
Tykodi SS. PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence. Onco Targets Ther. 2014;7:1349–1359.
-
(2014)
Onco Targets Ther
, vol.7
, pp. 1349-1359
-
-
Tykodi, SS.1
-
6
-
-
84924271853
-
Global cancer statistics, 2012
-
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
-
(2015)
CA Cancer J Clin
, vol.65
, Issue.2
, pp. 87-108
-
-
Torre, LA1
Bray, F2
Siegel, RL3
Ferlay, J4
Lortet-Tieulent, J5
Jemal, A.6
-
7
-
-
51649093834
-
Recent advances in head and neck cancer
-
Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med. 2008;359(11):1143–1154.
-
(2008)
N Engl J Med
, vol.359
, Issue.11
, pp. 1143-1154
-
-
Haddad, RI1
Shin, DM.2
-
8
-
-
0027921638
-
Head and neck cancer
-
Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med. 1993;328(3):184–194.
-
(1993)
N Engl J Med
, vol.328
, Issue.3
, pp. 184-194
-
-
Vokes, EE1
Weichselbaum, RR2
Lippman, SM3
Hong, WK.4
-
9
-
-
80051580618
-
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths
-
Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212–236.
-
(2011)
CA Cancer J Clin
, vol.61
, Issue.4
, pp. 212-236
-
-
Siegel, R1
Ward, E2
Brawley, O3
Jemal, A.4
-
10
-
-
84925296349
-
Therapeutic insights from genomic studies of head and neck squamous cell carcinomas
-
Hammerman PS, Hayes DN, Grandis JR. Therapeutic insights from genomic studies of head and neck squamous cell carcinomas. Cancer Discov. 2015;5(3):239–244.
-
(2015)
Cancer Discov
, vol.5
, Issue.3
, pp. 239-244
-
-
Hammerman, PS1
Hayes, DN2
Grandis, JR.3
-
11
-
-
34250180582
-
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy
-
Vermorken JB, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25(16):2171–2177.
-
(2007)
J Clin Oncol
, vol.25
, Issue.16
, pp. 2171-2177
-
-
Vermorken, JB1
-
12
-
-
84923197605
-
Comprehensive genomic characterization of head and neck squamous cell carcinomas
-
Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576–582.
-
(2015)
Nature
, vol.517
, Issue.7536
, pp. 576-582
-
-
-
13
-
-
84961289657
-
Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas
-
Seiwert TY, et al. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2015;21(3):632–641.
-
(2015)
Clin Cancer Res
, vol.21
, Issue.3
, pp. 632-641
-
-
Seiwert, TY1
-
14
-
-
80052177544
-
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1
-
Agrawal N, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011;333(6046):1154–1157.
-
(2011)
Science
, vol.333
, Issue.6046
, pp. 1154-1157
-
-
Agrawal, N1
-
15
-
-
80052158097
-
The mutational landscape of head and neck squamous cell carcinoma
-
Stransky N, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333(6046):1157–1160.
-
(2011)
Science
, vol.333
, Issue.6046
, pp. 1157-1160
-
-
Stransky, N1
-
16
-
-
84989299727
-
Efficacy safety of pembrolizumab in recurrent/metastatic head neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012 [abstract 6012]
-
Mehra R,et al. Efficacy safety of pembrolizumab in recurrent/metastatic head neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012 [abstract 6012]. J Clin Oncol. 2016;34.
-
(2016)
J Clin Oncol
, vol.34
-
-
Mehra, R1
-
17
-
-
85010325337
-
Nivolumab (nivo) vs investigator’s choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141
-
Paper presented at: April 19, New Orleans, LA
-
Gillison ML, et al. Nivolumab (nivo) vs investigator’s choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141. Paper presented at: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; April 19, 2016; New Orleans, LA.
-
(2016)
Proceedings of the 107th Annual Meeting of the American Association for Cancer Research
-
-
Gillison, ML1
-
18
-
-
84989351990
-
Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head neck (SCCHN): CheckMate 141 [abstract 6009]
-
Ferris RL, et al. Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head neck (SCCHN): CheckMate 141 [abstract 6009]. J Clin Oncol. 2016;34.
-
(2016)
J Clin Oncol
, vol.34
-
-
Ferris, RL1
-
20
-
-
84920962202
-
Molecular and genetic properties of tumors associated with local immune cytolytic activity
-
Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160(1-2):48–61.
-
(2015)
Cell
, vol.160
, Issue.1-2
, pp. 48-61
-
-
Rooney, MS1
Shukla, SA2
Wu, CJ3
Getz, G4
Hacohen, N.5
-
21
-
-
2342492313
-
Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression
-
Chung CH, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell. 2004;5(5):489–500.
-
(2004)
Cancer Cell
, vol.5
, Issue.5
, pp. 489-500
-
-
Chung, CH1
-
22
-
-
84874327940
-
Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes
-
Walter V, et al. Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes. PLoS One. 2013;8(2):e56823.
-
(2013)
PLoS One
, vol.8
, Issue.2
, pp. e56823
-
-
Walter, V1
-
23
-
-
84882837534
-
Signatures of mutational processes in human cancer
-
Alexandrov LB, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–421.
-
(2013)
Nature
, vol.500
, Issue.7463
, pp. 415-421
-
-
Alexandrov, LB1
-
24
-
-
67349186983
-
How cigarette smoke skews immune responses to promote infection, lung disease and cancer
-
Stämpfli MR, Anderson GP. How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat Rev Immunol. 2009;9(5):377–384.
-
(2009)
Nat Rev Immunol
, vol.9
, Issue.5
, pp. 377-384
-
-
Stämpfli, MR1
Anderson, GP.2
-
25
-
-
84928761118
-
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
-
Rizvi NA, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–128.
-
(2015)
Science
, vol.348
, Issue.6230
, pp. 124-128
-
-
Rizvi, NA1
-
26
-
-
84918828514
-
Genetic basis for clinical response to CTLA-4 blockade in melanoma
-
Snyder A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189–2199.
-
(2014)
N Engl J Med
, vol.371
, Issue.23
, pp. 2189-2199
-
-
Snyder, A1
-
27
-
-
84932628341
-
PD-1 blockade in tumors with mismatch-repair deficiency
-
Le DT, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–2520.
-
(2015)
N Engl J Med
, vol.372
, Issue.26
, pp. 2509-2520
-
-
Le, DT1
-
28
-
-
85020869806
-
Antitumor activity of the Anti-PD-1 antibody pembrolizumab in subgroups of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Exploratory analyses from KEYNOTE-012
-
Chow L, et al. Antitumor activity of the Anti-PD-1 antibody pembrolizumab in subgroups of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Exploratory analyses from KEYNOTE-012. Eur J Cancer. 2015;51(3):S579. doi: 10.1016/S0959-8049(16)31604-5.
-
(2015)
Eur J Cancer
, vol.51
, Issue.3
, pp. S579
-
-
Chow, L1
-
29
-
-
85136205070
-
Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort [abstract LBA6008]
-
Seiwert TY, et al. Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort [abstract LBA6008]. J Clin Oncol. 2015;33.
-
(2015)
J Clin Oncol
, vol.33
-
-
Seiwert, TY1
-
31
-
-
78650970845
-
Innate or adaptive immunity? The example of natural killer cells
-
Vivier E, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44–49.
-
(2011)
Science
, vol.331
, Issue.6013
, pp. 44-49
-
-
Vivier, E1
-
32
-
-
84951310757
-
NK cells and cancer: you can teach innate cells new tricks
-
Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer. 2016;16(1):7–19.
-
(2016)
Nat Rev Cancer
, vol.16
, Issue.1
, pp. 7-19
-
-
Morvan, MG1
Lanier, LL.2
-
33
-
-
84869856060
-
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
-
Vey N, et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood. 2012;120(22):4317–4323.
-
(2012)
Blood
, vol.120
, Issue.22
, pp. 4317-4323
-
-
Vey, N1
-
34
-
-
84942933304
-
A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma
-
Benson DM, et al. A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma. Clin Cancer Res. 2015;21(18):4055–4061.
-
(2015)
Clin Cancer Res
, vol.21
, Issue.18
, pp. 4055-4061
-
-
Benson, DM1
-
35
-
-
61449115971
-
CD56bright natural killer (NK) cells: an important NK cell subset
-
Poli A, Michel T, Thérésine M, Andrès E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009;126(4):458–465.
-
(2009)
Immunology
, vol.126
, Issue.4
, pp. 458-465
-
-
Poli, A1
Michel, T2
Thérésine, M3
Andrès, E4
Hentges, F5
Zimmer, J.6
-
36
-
-
77954190940
-
Human papillomavirus and survival of patients with oropharyngeal cancer
-
Ang KK, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35.
-
(2010)
N Engl J Med
, vol.363
, Issue.1
, pp. 24-35
-
-
Ang, KK1
-
37
-
-
84858800620
-
The immune contexture in human tumours: impact on clinical outcome
-
Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298–306.
-
(2012)
Nat Rev Cancer
, vol.12
, Issue.4
, pp. 298-306
-
-
Fridman, WH1
Pagès, F2
Sautès-Fridman, C3
Galon, J.4
-
38
-
-
36849010167
-
Adaptive immunity maintains occult cancer in an equilibrium state
-
Koebel CM, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007;450(7171):903–907.
-
(2007)
Nature
, vol.450
, Issue.7171
, pp. 903-907
-
-
Koebel, CM1
-
39
-
-
0035953308
-
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity
-
Shankaran V, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410(6832):1107–1111.
-
(2001)
Nature
, vol.410
, Issue.6832
, pp. 1107-1111
-
-
Shankaran, V1
-
40
-
-
33749319703
-
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
-
Galon J, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–1964.
-
(2006)
Science
, vol.313
, Issue.5795
, pp. 1960-1964
-
-
Galon, J1
-
41
-
-
79952284127
-
Hallmarks of cancer: the next generation
-
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
-
(2011)
Cell
, vol.144
, Issue.5
, pp. 646-674
-
-
Hanahan, D1
Weinberg, RA.2
-
42
-
-
47949096781
-
Cancer-related inflammation
-
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–444.
-
(2008)
Nature
, vol.454
, Issue.7203
, pp. 436-444
-
-
Mantovani, A1
Allavena, P2
Sica, A3
Balkwill, F.4
-
43
-
-
84938984463
-
The prognostic landscape of genes and infiltrating immune cells across human cancers
-
Gentles AJ, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938–945.
-
(2015)
Nat Med
, vol.21
, Issue.8
, pp. 938-945
-
-
Gentles, AJ1
-
44
-
-
84866754237
-
An immunosurveillance mechanism controls cancer cell ploidy
-
Senovilla L, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science. 2012;337(6102):1678–1684.
-
(2012)
Science
, vol.337
, Issue.6102
, pp. 1678-1684
-
-
Senovilla, L1
-
45
-
-
78049248432
-
Allele-specific copy number analysis of tumors
-
Van Loo P, et al. Allele-specific copy number analysis of tumors. Proc Natl Acad Sci USA. 2010;107(39):16910–16915.
-
(2010)
Proc Natl Acad Sci USA
, vol.107
, Issue.39
, pp. 16910-16915
-
-
Van Loo, P1
-
46
-
-
84885673911
-
Inferring tumour purity and stromal and immune cell admixture from expression data
-
Yoshihara K, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.
-
(2013)
Nat Commun
, vol.4
, pp. 2612
-
-
Yoshihara, K1
-
47
-
-
84922394461
-
Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss
-
Gross AM, et al. Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. Nat Genet. 2014;46(9):939–943.
-
(2014)
Nat Genet
, vol.46
, Issue.9
, pp. 939-943
-
-
Gross, AM1
-
48
-
-
43749112760
-
Vascular normalization in Rgs5-deficient tumours promotes immune destruction
-
Hamzah J, et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature. 2008;453(7193):410–414.
-
(2008)
Nature
, vol.453
, Issue.7193
, pp. 410-414
-
-
Hamzah, J1
-
49
-
-
84901290212
-
Releasing pressure in tumors: what do we know so far and where do we go from here? A review
-
Ariffin AB, Forde PF, Jahangeer S, Soden DM, Hinchion J. Releasing pressure in tumors: what do we know so far and where do we go from here? A review. Cancer Res. 2014;74(10):2655–2662.
-
(2014)
Cancer Res
, vol.74
, Issue.10
, pp. 2655-2662
-
-
Ariffin, AB1
Forde, PF2
Jahangeer, S3
Soden, DM4
Hinchion, J.5
-
50
-
-
33748987908
-
Cancer despite immunosurveillance: immunoselection and immunosubversion
-
Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006;6(10):715–727.
-
(2006)
Nat Rev Immunol
, vol.6
, Issue.10
, pp. 715-727
-
-
Zitvogel, L1
Tesniere, A2
Kroemer, G.3
-
51
-
-
2442585121
-
Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity
-
Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol. 2004;4(5):336–347.
-
(2004)
Nat Rev Immunol
, vol.4
, Issue.5
, pp. 336-347
-
-
Chen, L.1
-
52
-
-
44349150012
-
Inhibitory B7-family molecules in the tumour microenvironment
-
Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8(6):467–477.
-
(2008)
Nat Rev Immunol
, vol.8
, Issue.6
, pp. 467-477
-
-
Zou, W1
Chen, L.2
-
53
-
-
18544380239
-
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion
-
Dong H, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800.
-
(2002)
Nat Med
, vol.8
, Issue.8
, pp. 793-800
-
-
Dong, H1
-
54
-
-
34447646310
-
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
-
Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27(1):111–122.
-
(2007)
Immunity
, vol.27
, Issue.1
, pp. 111-122
-
-
Butte, MJ1
Keir, ME2
Phamduy, TB3
Sharpe, AH4
Freeman, GJ.5
-
55
-
-
68149155982
-
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
-
Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009;206(8):1717–1725.
-
(2009)
J Exp Med
, vol.206
, Issue.8
, pp. 1717-1725
-
-
Peggs, KS1
Quezada, SA2
Chambers, CA3
Korman, AJ4
Allison, JP.5
-
56
-
-
84878936788
-
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells
-
Selby MJ, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 2013;1(1):32–42.
-
(2013)
Cancer Immunol Res
, vol.1
, Issue.1
, pp. 32-42
-
-
Selby, MJ1
-
57
-
-
84884271914
-
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
-
Simpson TR, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013;210(9):1695–1710.
-
(2013)
J Exp Med
, vol.210
, Issue.9
, pp. 1695-1710
-
-
Simpson, TR1
-
58
-
-
84942138310
-
Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D [abstract 8011]
-
Patnaik A, et al. Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D [abstract 8011]. J Clin Oncol. 2015;33.
-
(2015)
J Clin Oncol
, vol.33
-
-
Patnaik, A1
-
59
-
-
79957936035
-
Indoleamine 2,3-dioxygenase, Tregs and cancer
-
Munn DH. Indoleamine 2,3-dioxygenase, Tregs and cancer. Curr Med Chem. 2011;18(15):2240–2246.
-
(2011)
Curr Med Chem
, vol.18
, Issue.15
, pp. 2240-2246
-
-
Munn, DH.1
-
60
-
-
84897933432
-
GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability
-
Schaer DA, et al. GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. Cancer Immunol Res. 2013;1(5):320–331.
-
(2013)
Cancer Immunol Res
, vol.1
, Issue.5
, pp. 320-331
-
-
Schaer, DA1
-
61
-
-
84874996294
-
ICOS controls Foxp3(+) regulatory T-cell expansion, maintenance and IL-10 production during helminth infection
-
Redpath SA, et al. ICOS controls Foxp3(+) regulatory T-cell expansion, maintenance and IL-10 production during helminth infection. Eur J Immunol. 2013;43(3):705–715.
-
(2013)
Eur J Immunol
, vol.43
, Issue.3
, pp. 705-715
-
-
Redpath, SA1
-
62
-
-
84977564001
-
Personalized oncology meets immunology: the path toward precision immunotherapy
-
Mandal R, Chan TA. Personalized oncology meets immunology: the path toward precision immunotherapy. Cancer Discov. 2016;6(7):703–713.
-
(2016)
Cancer Discov
, vol.6
, Issue.7
, pp. 703-713
-
-
Mandal, R1
Chan, TA.2
-
63
-
-
78149281950
-
A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients
-
Adotevi O, et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother. 2010;33(9):991–998.
-
(2010)
J Immunother
, vol.33
, Issue.9
, pp. 991-998
-
-
Adotevi, O1
-
64
-
-
0034715948
-
Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population
-
Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000;356(9244):1795–1799.
-
(2000)
Lancet
, vol.356
, Issue.9244
, pp. 1795-1799
-
-
Imai, K1
Matsuyama, S2
Miyake, S3
Suga, K4
Nakachi, K.5
-
65
-
-
0022476775
-
Natural killer cell activity and head and neck cancer: a clinical assessment
-
Schantz SP, Shillitoe EJ, Brown B, Campbell B. Natural killer cell activity and head and neck cancer: a clinical assessment. J Natl Cancer Inst. 1986;77(4):869–875.
-
(1986)
J Natl Cancer Inst
, vol.77
, Issue.4
, pp. 869-875
-
-
Schantz, SP1
Shillitoe, EJ2
Brown, B3
Campbell, B.4
-
66
-
-
0027368830
-
Role of natural killer cells in cancer
-
Pross HF, Lotzová E. Role of natural killer cells in cancer. Nat Immun. 1993;12(4-5):279–292.
-
(1993)
Nat Immun
, vol.12
, Issue.4-5
, pp. 279-292
-
-
Pross, HF1
Lotzová, E.2
-
67
-
-
0019193024
-
Role of natural killer cells in tumor growth and metastasis: C57BL/6 normal and beige mice
-
Talmadge JE, Meyers KM, Prieur DJ, Starkey JR. Role of natural killer cells in tumor growth and metastasis: C57BL/6 normal and beige mice. J Natl Cancer Inst. 1980;65(5):929–935.
-
(1980)
J Natl Cancer Inst
, vol.65
, Issue.5
, pp. 929-935
-
-
Talmadge, JE1
Meyers, KM2
Prieur, DJ3
Starkey, JR.4
-
68
-
-
84875509728
-
Regulation of ligands for the NKG2D activating receptor
-
Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol. 2013;31:413–441.
-
(2013)
Annu Rev Immunol
, vol.31
, pp. 413-441
-
-
Raulet, DH1
Gasser, S2
Gowen, BG3
Deng, W4
Jung, H.5
-
69
-
-
84899004889
-
Natural cytotoxicity receptors and their ligands
-
Kruse PH, Matta J, Ugolini S, Vivier E. Natural cytotoxicity receptors and their ligands. Immunol Cell Biol. 2014;92(3):221–229.
-
(2014)
Immunol Cell Biol
, vol.92
, Issue.3
, pp. 221-229
-
-
Kruse, PH1
Matta, J2
Ugolini, S3
Vivier, E.4
-
70
-
-
84902137525
-
Targeting CD137 enhances the efficacy of cetuximab
-
Kohrt HE, et al. Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest. 2014;124(6):2668–2682.
-
(2014)
J Clin Invest
, vol.124
, Issue.6
, pp. 2668-2682
-
-
Kohrt, HE1
-
71
-
-
84925743331
-
Balancing natural killer cell activation through paired receptors
-
Martinet L, Smyth MJ. Balancing natural killer cell activation through paired receptors. Nat Rev Immunol. 2015;15(4):243–254.
-
(2015)
Nat Rev Immunol
, vol.15
, Issue.4
, pp. 243-254
-
-
Martinet, L1
Smyth, MJ.2
-
72
-
-
84864999052
-
PD-1 expression on natural killer cells and CD8(+) T cells during chronic HIV-1 infection
-
Norris S, Coleman A, Kuri-Cervantes L, Bower M, Nelson M, Goodier MR. PD-1 expression on natural killer cells and CD8(+) T cells during chronic HIV-1 infection. Viral Immunol. 2012;25(4):329–332.
-
(2012)
Viral Immunol
, vol.25
, Issue.4
, pp. 329-332
-
-
Norris, S1
Coleman, A2
Kuri-Cervantes, L3
Bower, M4
Nelson, M5
Goodier, MR.6
-
73
-
-
77957701558
-
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
-
Benson DM, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010;116(13):2286–2294.
-
(2010)
Blood
, vol.116
, Issue.13
, pp. 2286-2294
-
-
Benson, DM1
-
74
-
-
84958555198
-
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
-
Koyama S, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7:10501.
-
(2016)
Nat Commun
, vol.7
, pp. 10501
-
-
Koyama, S1
-
75
-
-
78049243425
-
Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth
-
Teng MW, Ngiow SF, von Scheidt B, McLaughlin N, Sparwasser T, Smyth MJ. Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. Cancer Res. 2010;70(20):7800–7809.
-
(2010)
Cancer Res
, vol.70
, Issue.20
, pp. 7800-7809
-
-
Teng, MW1
Ngiow, SF2
von Scheidt, B3
McLaughlin, N4
Sparwasser, T5
Smyth, MJ.6
-
76
-
-
84928199174
-
STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
-
Fu J, et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Transl Med. 2015;7(283):283ra52.
-
(2015)
Sci Transl Med
, vol.7
, Issue.283
, pp. 283ra52
-
-
Fu, J1
-
77
-
-
84885137302
-
Exploring TCGA Pan-Cancer data at the UCSC Cancer Genomics Browser
-
Cline MS, et al. Exploring TCGA Pan-Cancer data at the UCSC Cancer Genomics Browser. Sci Rep. 2013;3:2652.
-
(2013)
Sci Rep
, vol.3
, pp. 2652
-
-
Cline, MS1
-
78
-
-
84885724091
-
Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer
-
Bindea G, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782–795.
-
(2013)
Immunity
, vol.39
, Issue.4
, pp. 782-795
-
-
Bindea, G1
-
79
-
-
70449091786
-
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
-
Barbie DA, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462(7269):108–112.
-
(2009)
Nature
, vol.462
, Issue.7269
, pp. 108-112
-
-
Barbie, DA1
-
80
-
-
84928927858
-
Robust enumeration of cell subsets from tissue expression profiles
-
Newman AM, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457.
-
(2015)
Nat Methods
, vol.12
, Issue.5
, pp. 453-457
-
-
Newman, AM1
-
81
-
-
84891102589
-
Mutational signatures: the patterns of somatic mutations hidden in cancer genomes
-
Alexandrov LB, Stratton MR. Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. Curr Opin Genet Dev. 2014;24:52–60.
-
(2014)
Curr Opin Genet Dev
, vol.24
, pp. 52-60
-
-
Alexandrov, LB1
Stratton, MR.2
|